Compare SSM & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSM | GOVX |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | Germany | United States |
| Employees | 23 | 19 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.2M |
| IPO Year | N/A | N/A |
| Metric | SSM | GOVX |
|---|---|---|
| Price | $3.90 | $1.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 6.8K | ★ 524.2K |
| Earning Date | 05-20-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,462,987.20 | N/A |
| Revenue Next Year | $48.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.42 | $0.12 |
| 52 Week High | $10.54 | $4.40 |
| Indicator | SSM | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 40.60 |
| Support Level | $3.61 | $1.17 |
| Resistance Level | $4.49 | $2.00 |
| Average True Range (ATR) | 0.49 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 20.00 | 16.67 |
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and services include Complete Solar Solutions, Solar Charge Controllers, Solar Modules, Data Services, and Engineering Services. The company's single business segment manages the financing, research and development, and product commercialization.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.